[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent (NUVL) stock ripped higher on June 9 after GSK (GSK) announced a $10.6 billion all-cash deal to acquire the Nasdaq-listed precision oncology company. 

The British pharmaceutical behemoth will commence a tender offer at $124 per share, representing a massive 40% premium on NUVL’s previous close. 

Fundamentals

See More
  • Market Capitalization, $K 146,019,760
  • Shares Outstanding, K 5,699,444
  • Annual Sales, $ 62,579 M
  • Annual Income, $ 7,771 M
  • EBIT $ 19,384 M
  • EBITDA $ 25,976 M
  • 60-Month Beta 0.34
  • Price/Sales 2.37
  • Price/Cash Flow 5.92
  • Price/Book 1.64

Options Overview Details

View History
  • Implied Volatility 22.58% (-0.08%)
  • Historical Volatility 17.38%
  • IV Percentile 19%
  • IV Rank 27.24%
  • IV High 34.15% on 10/10/25
  • IV Low 18.25% on 08/18/25
  • Expected Move (DTE 3) 0.43 (1.69%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 86,397
  • Volume Avg (30-Day) 105,795
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 2,626,092
  • Open Int (30-Day) 2,595,445
  • Expected Range 25.27 to 26.13

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 28 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.68
  • Number of Estimates 6
  • High Estimate $0.72
  • Low Estimate $0.66
  • Prior Year $0.78
  • Growth Rate Est. (year over year) -12.82%

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.19 +2.02%
on 05/18/26
26.53 -3.15%
on 05/27/26
+0.02 (+0.08%)
since 05/08/26
3-Month
25.19 +2.02%
on 05/18/26
28.75 -10.59%
on 04/02/26
-1.11 (-4.14%)
since 03/09/26
52-Week
23.11 +11.21%
on 08/01/25
28.75 -10.59%
on 04/02/26
+1.73 (+7.22%)
since 06/09/25

Most Recent Stories

More News
Nuvalent Stock Hits All-Time High Following GSK's Buyout Offer

Nuvalent shares soar as GSK announces a $10.6 billion buyout deal. But is it too late already to invest in NUVL stock?

NUVL : 123.25 (+39.28%)
RHHBY : 50.2300 (-0.63%)
GSK : 51.25 (+1.20%)
PFE : 25.70 (+0.31%)
U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

Approval expands HYMPAVZI use to now include people with hemophilia A or B ages 12 years and older with inhibitors and pediatric patients (ages 6 to 11 years) with or without inhibitors ...

PFE : 25.70 (+0.31%)
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer’s GLP-1 RA Berobenatide

Results from multiple Phase 2b dose finding studies for berobenatide (PF’3944) highlight a potential first-in-class monthly GLP-1 receptor agonist (GLP-1 RA) peptide, and support the planned Phase 3...

PFE : 25.70 (+0.31%)
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 47th Annual Global...

PFE : 25.70 (+0.31%)
3 Cash-Producing Stocks Worth Your Attention

3 Cash-Producing Stocks Worth Your Attention

SE : 84.87 (+0.45%)
OSIS : 215.39 (+2.33%)
PFE : 25.70 (+0.31%)
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer

Cohort 3 analysis from the Phase 3 BREAKWATER study showed a 56% reduction in the risk of disease progression or death compared to traditional chemotherapy regimen ...

PFE : 25.70 (+0.31%)
How Is Pfizer's Stock Performance Compared to Other Healthcare Stocks?

Due to Pfizer’s underperformance relative to its peers over the past year, Wall Street analysts remain cautious about the stock’s prospects

XLV : 154.57 (+1.26%)
AMGN : 344.57 (-0.34%)
PFE : 25.70 (+0.31%)
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer

First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both BRCA and non‑BRCA alterations ...

PFE : 25.70 (+0.31%)
Seven-Year Analysis from Pfizer’s LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer

Patients had a 55% likelihood of remaining alive without disease progression at seven years, and median progression-free survival was not reached with LORBRENA ...

PFE : 25.70 (+0.31%)
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines

Pfizer Inc. (NYSE: PFE) and Innovent Biologics, Inc. (01801.HK), today announced the companies have entered into a strategic global licensing and collaboration agreement for the research and development...

PFE : 25.70 (+0.31%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 26.31
2nd Resistance Point 26.09
1st Resistance Point 25.90
Last Price 25.70
1st Support Level 25.49
2nd Support Level 25.27
3rd Support Level 25.08

See More

52-Week High 28.75
Fibonacci 61.8% 26.59
Fibonacci 50% 25.93
Last Price 25.70
Fibonacci 38.2% 25.26
52-Week Low 23.11

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.